Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Authors
Keywords
-
Journal
BLOOD
Volume 121, Issue 19, Pages 3818-3824
Publisher
American Society of Hematology
Online
2013-03-21
DOI
10.1182/blood-2012-10-462291
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
- (2012) J. Guilhot et al. BLOOD
- Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
- (2012) D. Marin et al. BLOOD
- Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
- (2012) F. Guilhot et al. HAEMATOLOGICA
- Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
- (2012) Susan Branford et al. JOURNAL OF CLINICAL ONCOLOGY
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
- (2012) Ho-Young Yhim et al. LEUKEMIA RESEARCH
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
- (2011) M. Tang et al. BLOOD
- BCR-ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment
- (2011) A. M. Stein et al. CLINICAL CANCER RESEARCH
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
- (2011) M Pfirrmann et al. LEUKEMIA
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response
- (2010) A. Kuwabara et al. BLOOD
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
- (2010) D M Ross et al. LEUKEMIA
- Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses
- (2010) D. Wodarz PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
- (2009) Hyun-Gyung Goh et al. LEUKEMIA & LYMPHOMA
- Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- (2008) T. P. Hughes et al. BLOOD
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Development and dynamics of robust T-cell responses to CML under imatinib treatment
- (2008) C. I-U. Chen et al. BLOOD
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started